Zobrazeno 1 - 10
of 26
pro vyhledávání: '"Simon Fear"'
Autor:
Richard Cathomas, Julian Schardt, Miklos Pless, Anna Llado, Nicolas Mach, Christian Riklin, Jenny Haefeli, Simon Fear, Frank Stenner
Publikováno v:
Swiss Medical Weekly, Vol 150, Iss 1920 (2020)
AIMS OF THE STUDY Atezolizumab is an approved therapy for urothelial carcinoma based on results from the IMvigor 210 and IMvigor211 phase II and III trials. The global SAUL study evaluated atezolizumab in a broader patient population more representa
Externí odkaz:
https://doaj.org/article/ec31e6e2ddb04c69820db92a09ed3495
Autor:
Hina, Patel, Thanh G N, Ton, Jessica, Davies, Simon, Fear, Carolin, Block, Kunihiko, Tanaka, Danny, Gonzalez, Roger, Mutter, Noelia, Alfaro-Oliver, Ignacio, Mendez, Nawab, Qizilbash
Publikováno v:
Pharmaceutical Medicine
Background A Guide for Healthcare Professionals (HCP Guide) and patient alert card (PAC) for atezolizumab as additional risk minimization measures for physicians were distributed to raise awareness and help in the detection and management of immune-r
Autor:
Daniel P. Petrylak, Robert Dreicer, Sabine de Ducla, Michiel S. van der Heijden, Jens Bedke, Jonathan E. Rosenberg, Thomas Powles, Yohann Loriot, Jose Luis Perez-Gracia, Simon Fear, Ernest Choy, Lars Thiebach, Axel S. Merseburger, Ignacio Duran, Cora N. Sternberg, Julie Pavlova, Daniel Castellano, Jean H. Hoffman-Censits
Publikováno v:
European urology focus, 7(5), 1084-1091. Elsevier BV
Background The value of a complete response to immune checkpoint inhibitor treatment for urothelial cancer is well recognised, but less is known about long-term outcomes in patients with a partial response or the benefit of achieving disease stabilis
Autor:
Simon Fear
Publikováno v:
British Dental Journal. 230:444-446
This is the tale of two soldiers serving in the Army Dental Corps, who conducted an unsupported and unauthorised commando mission into occupied France during World War II (WW2). In 1942, Sergeant King and Private Cuthbertson planned and executed one
Autor:
Michiel S. van der Heijden, Robert Huddart, Margitta Retz, Julie Pavlova, Sabine de Ducla, Cora N. Sternberg, Thomas Powles, Simon Fear, Jens Voortman, Michael Ong, Howard Gurney, Craig Gedye, Axel S. Merseburger, Daniel Castellano, Yohann Loriot
Publikováno v:
Merseburger, A S, Castellano, D, Powles, T, Loriot, Y, Retz, M, Voortman, J, Huddart, R A, Gedye, C, Van Der Heijden, M S, Gurney, H, Ong, M, de Ducla, S, Pavlova, J, Fear, S & Sternberg, C N 2021, ' Safety and Efficacy of Atezolizumab in Understudied Populations with Pretreated Urinary Tract Carcinoma : Subgroup Analyses of the SAUL Study in Real-World Practice ', The Journal of Urology, vol. 206, no. 2, pp. 240-251 . https://doi.org/10.1097/JU.0000000000001768
The Journal of Urology, 206(2), 240-251. Elsevier Inc.
The Journal of Urology, 206(2), 240-251. Elsevier Inc.
PURPOSE: Atezolizumab is an established treatment option for pretreated urothelial carcinoma, demonstrating efficacy in phase II/III trials. The SAUL study enrolled a broader patient population to determine safety and efficacy in underrepresented sub
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::33498fc9da17966238e1e61b65d590d0
https://research.vumc.nl/en/publications/8ecb94d2-761a-4289-84db-952c5b7aa987
https://research.vumc.nl/en/publications/8ecb94d2-761a-4289-84db-952c5b7aa987
Autor:
Rodrigo Dienstmann, Clare Turnbull, Allan Hackshaw, Jean-Yves Blay, Maud Kamal, Nicolas Servant, Jan Geissler, David Tamborero, Janick Weberpals, Simon Fear, Camille Perret, Laura Perez, Martina von Meyenn, Christophe Le Tourneau
Publikováno v:
Cancer Research. 82:5246-5246
In precision oncology, tailored treatment decisions are largely driven by genomic alterations in a patient’s tumor. To support epidemiological research, we initiated a registry that enrolls patients diagnosed with a solid tumor and profiled with NG
Autor:
Franco Nolè, Iwona Skoneczna, Francesco Massari, Sabine de Ducla, Sjoukje F. Oosting, Robert Huddart, Herlinde Dumez, Ernest Choy, Pablo Maroto, Birute Brasiuniene, Daniel Castellano, Cora N. Sternberg, Yohann Loriot, Teresa Alonso Gordoa, Flavia Di Nucci, Andre P. Fay, Karina Vianna, Simon Fear
Publikováno v:
EUROPEAN JOURNAL OF CANCER
r-IIB SANT PAU: Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
Institut dInvestigació Biomèdica Sant Pau (IIB Sant Pau)
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
European Journal of Cancer, 138, 202-211. ELSEVIER SCI LTD
r-IIB SANT PAU: Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
Institut dInvestigació Biomèdica Sant Pau (IIB Sant Pau)
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
European Journal of Cancer, 138, 202-211. ELSEVIER SCI LTD
Aim: Patients with pre-existing autoimmune disease (AID) are typically excluded from clinical trials of immune checkpoint inhibitors, and there are limited data on outcomes in this population. The single-arm international SAUL study of atezolizumab e
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2ca329aacc3d0499c2cc1da1bda62b62
https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=1357
https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=1357
Autor:
Andre P. Fay, Begoña Mellado, Craig Gedye, Michael Ong, Simon Fear, Sabine de Ducla, Michaela Matouskova, Laura Milesi, Aristotelis Bamias, Giuseppe Fornarini, Florian Seseke, Michal Mego, Howard Gurney, Jason F. Lester, Daniel Castellano, Robert Huddart, Cora N. Sternberg, Filipa Carneiro, Shahrokh F. Shariat, Jens Voortman
Publikováno v:
Voortman, J 2020, ' Atezolizumab (atezo) therapy for locally advanced/metastatic urinary tract carcinoma (mUTC) in patients (pts) with poor performance status (PS): Analysis of the prospective global SAUL study. ', ASCO 2020 Virtual Annual Meeting, 01/06/2020 . https://doi.org/10.1200/JCO.2020.38.15_suppl.5035
Castellano, D, Gedye, C, Fornarini, G, Fay, A P, Voortman, J, Mego, M, Bamias, A, Lester, J F, Huddart, R A, Matouskova, M, Gurney, H, Mellado, B, Ong, M, Carneiro, F, Seseke, F, Milesi, L, Shariat, S F, Fear, S, de Ducla, S & Sternberg, C N 2020, ' Atezolizumab (atezo) therapy for locally advanced/metastatic urinary tract carcinoma (mUTC) in patients (pts) with poor performance status (PS): Analysis of the prospective global SAUL study. ', Journal of Clinical Oncology, vol. 38, no. 15 .
Journal of Clinical Oncology, 38(15). American Society of Clinical Oncology
ASCO 2020 Virtual Annual Meeting
Castellano, D, Gedye, C, Fornarini, G, Fay, A P, Voortman, J, Mego, M, Bamias, A, Lester, J F, Huddart, R A, Matouskova, M, Gurney, H, Mellado, B, Ong, M, Carneiro, F, Seseke, F, Milesi, L, Shariat, S F, Fear, S, de Ducla, S & Sternberg, C N 2020, ' Atezolizumab (atezo) therapy for locally advanced/metastatic urinary tract carcinoma (mUTC) in patients (pts) with poor performance status (PS): Analysis of the prospective global SAUL study. ', Journal of Clinical Oncology, vol. 38, no. 15 .
Journal of Clinical Oncology, 38(15). American Society of Clinical Oncology
ASCO 2020 Virtual Annual Meeting
5035 Background: Pts with PS > 1 have a poor prognosis and are often excluded from clinical trials. The single-arm SAUL study (NCT02928406) evaluated atezo in a ‘real-world’ population. Overall, safety and efficacy were consistent with prior tria
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0ef5cbd4bf0d0e7f1c8c1789adacc962
https://research.vumc.nl/en/publications/d5a561d2-da51-4065-ba25-0af28a6d2458
https://research.vumc.nl/en/publications/d5a561d2-da51-4065-ba25-0af28a6d2458
Autor:
Filippo Montemurro, Rachel Wuerstlein, Suzette Delaloge, Simon Fear, Andhika Rachman, Claudia Pena-Murillo, Shusen Wang, Huiping Li, Haiying Liu, Xiaojia Wang, Carlos H. Barrios, Mawin Vongsaisuwon, Shao Zhi-min, Qingyuan Zhang, Paul Anthony Ellis, Antonio Antón Torres
Publikováno v:
Journal of Clinical Oncology. 39:1039-1039
1039 Background: KAMILLA is an open-label, single-arm, phase 3b safety study of T-DM1 in pts with HER2-positive advanced BC (NCT01702571). The treated (safety) population of KAMILLA comprises 2 cohorts: a larger global Cohort 1 (n=2002) and a smaller
Autor:
Marija Gamulin, Simon Fear, Thomas Powles, Lajos Géczi, Cora N. Sternberg, Fernando Lopez-Rios, Yohann Loriot, Craig Gedye, Xavier Garcia del Muro, Giuseppe Luigi Banna, Ugo De Giorgi, Friedemann Zengerling, Ignacio Duran, Nicholas D. James, Aristotelis Bamias, Sabine de Ducla, Daniel Castellano, Cristina Masini, Axel S. Merseburger, Ernest Choy
Publikováno v:
Dipòsit Digital de la UB
Universidad de Barcelona
Universidad de Barcelona
Background Atezolizumab, a humanised monoclonal antibody targeting PD-L1, is approved for locally advanced/metastatic urothelial carcinoma. SAUL evaluated atezolizumab in a broader, pretreated population, including patients ineligible for the pivotal
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d85ce0d18632cfec253bc60afd1ec8c9
https://hdl.handle.net/10668/13756
https://hdl.handle.net/10668/13756